MwanzoAGIO • BMV
add
Agios Pharmaceuticals Inc
Bei iliyotangulia
$ 983.02
Bei za mwaka
$ 397.93 - $ 983.02
Thamani ya kampuni katika soko
3.18B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 8.96M | 21.15% |
Matumizi ya uendeshaji wa biashara | 38.54M | 49.24% |
Mapato halisi | 947.92M | 1,137.97% |
Kiwango cha faida halisi | elfu 10.57 | 956.76% |
Mapato kwa kila hisa | -1.47 | 10.66% |
EBITDA | -101.47M | -2.21% |
Asilimia ya kodi ya mapato | 5.31% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 1.00B | 55.18% |
Jumla ya mali | 1.79B | 77.89% |
Jumla ya dhima | 165.12M | 37.13% |
Jumla ya hisa | 1.63B | — |
hisa zilizosalia | 57.03M | — |
Uwiano wa bei na thamani | 34.46 | — |
Faida inayotokana na mali | -20.04% | — |
Faida inayotokana mtaji | -21.31% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 947.92M | 1,137.97% |
Pesa kutokana na shughuli | -84.22M | -36.62% |
Pesa kutokana na uwekezaji | 250.79M | 537.49% |
Pesa kutokana na ufadhili | 2.64M | 40.12% |
Mabadiliko halisi ya pesa taslimu | 169.21M | 928.66% |
Mtiririko huru wa pesa | -3.03M | 95.64% |
Kuhusu
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Ilianzishwa
2008
Tovuti
Wafanyakazi
385
